7 Reasons to Invest in Epi One: Transforming Cancer Detection
Imagine a world where a simple test could detect cancer at its earliest stages, long before symptoms appear. A world where millions of lives could be saved through early intervention. This isn’t science fiction—it’s the reality Epi One is working to create, and you can be part of this transformative journey.
What is Epi One?
We believe Epi One is a biotechnology company that develops advanced DNA-based biomarker identification methods for early cancer detection. Our technology aims to identify cancer-specific markers in the bloodstream with unprecedented accuracy and affordability, potentially revolutionizing how we approach cancer diagnosis and treatment. We are confident in our technology and have had many third-party validations to confirm our claim of 98% accuracy. The company is currently pre-revenue.
Why Epi One Matters
Cancer remains one of the leading causes of death worldwide. Despite significant advancements in treatment, early detection remains the most crucial factor in improving survival rates. Epi One’s technology can shift the paradigm from reactive treatment to proactive prevention, potentially saving millions of lives and billions in healthcare costs.
Top Reasons to Invest in Epi One
1. Addressing a Critical Need
Our technology targets one of the most pressing issues in healthcare today. By focusing on early detection, we’re not just improving treatment outcomes—we’re working to prevent the devastating impact of late-stage cancer diagnoses.
2. Significant Market Potential
The U.S. Cancer Diagnostics Market is projected to reach $70 billion by 2032. As a company at the forefront of this field, Epi One is well-positioned to capture a significant portion of this growing market.
3. Distinctive Technological Approach
We believe Epi One’s DNA-based biomarker identification method stands out in cancer diagnostics. Our approach focuses on a different part of the genome than conventional methods, allowing us to potentially detect cancer signals earlier and more accurately than current tests. We think this distinctive methodology could offer several advantages:
- Earlier Detection: By identifying cancer-specific markers that appear in the earliest stages of the disease, we aim to catch cancer before it becomes symptomatic or spreads.
- Improved Accuracy: Our technology is designed to reduce false positives and negatives, potentially leading to more reliable diagnoses and reducing unnecessary anxiety or procedures.
- Cost-Effectiveness: Our tests aim to be more affordable than comprehensive genetic screenings by focusing on specific biomarkers, making regular cancer checks more accessible to a broader population.
- Versatility: While we’re starting with specific cancer types, our technology has the potential to be adapted for detecting various forms of cancer, expanding its utility and market potential.
We think this technological foundation not only sets Epi One apart in the cancer diagnostics field but also provides a strong basis for long-term growth and development in the expanding personalized medicine market.
4. Experienced Leadership
Epi One’s leadership combines top-tier scientific knowledge with strategic business acumen. CEO Michael Marquardt brings extensive business and nonprofit experience, providing a strong foundation for our mission-driven approach.
Co-founders lead our scientific team with impressive credentials:
- Dr. Sophia Fang, MD, PhD, our President and Chief Scientific Officer, brings invaluable expertise from her research at Memorial Sloan Kettering Cancer Center. Her background in genomics and cancer biology is crucial to our clinical strategy.
- Dr. Neng Yang, MD, PhD, our Vice President of Research & Development, is a pioneer in next-gen sequencing and CAR T-cell therapy. Her experience at Sloan Kettering, where she developed single-cell sorting for leukemia and researched innovative cancer therapies, drives our biomarker validation efforts.
This combination of business strategy and cutting-edge scientific expertise from one of the world’s leading cancer research institutions positions Epi One at the forefront of cancer diagnostics innovation. Our team’s diverse background in oncology, molecular biology, and biotech commercialization ensures we have the knowledge and skills to navigate the complex path from research to market.
5. Potential for Wide-Reaching Impact
Our technology isn’t limited to a single type of cancer. The adaptability of our approach means we could potentially develop tests for multiple cancer types, expanding our impact and market reach.
6. The Opportunity of Early-Stage Investment
Investing in Epi One at this pre-revenue stage offers a unique opportunity to acquire a stake at the company’s lowest valuation point. Each successful milestone, such as positive trial results or regulatory approvals, represents great value for the company.
Epi One is working to address needs in the cancer diagnostics market, which is projected to reach $70 billion by 2032. Early investors have the chance to be part of our journey as we develop our cancer detection technology.
7. Intellectual Property Protection
Our proprietary technology is protected by patents and focused on applications our technology serves, providing a competitive advantage and potential for licensing opportunities.
Our highly esteemed patent lawyer has advised us only to patent the applications, holding trade secrets internally – we believe this is highly valuable. The secret sauce, like Coca-Cola’s recipe, is intentionally not patented.
Join Us in Transforming Cancer Detection
Investing in Epi One isn’t just a financial decision—it’s an opportunity to be part of a movement that could fundamentally change how we approach cancer. By detecting cancer earlier, we believe we can make it less scary and more treatable for millions worldwide.
As we continue to advance our technology and move towards clinical trials, early investors can join us at a pivotal moment in our journey. Your investment could help accelerate our progress and bring this life-saving technology to market sooner.
Are you ready to be part of a future where cancer is detected early enough to cure and accurately enough to treat effectively? Join us in our mission to transform cancer detection and create a healthier future for all.
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
